Updated on 28 January 2014
Singapore: Takeda Development Center Shanghai (TDC Shanghai) and Takeda Development Center Asia has commenced TOURMALINE-MM1 global Phase 3 study in Asia for Takeda's oral proteasome inhibitor, ixazomib, in relapsed and/or refractory multiple myeloma (MM).
Countries participating in the study include Australia, China, Japan, New Zealand, Singapore and South Korea. This will be the second Phase 3 oncology study conducted by Takeda in China.
Ixazomib is an investigational oral, proteasome inhibitor, which is being studied in multiple myeloma and other malignancies. It is the first oral proteasome inhibitor to enter Phase 3 clinical trials. As an investigational oral proteasome inhibitor, it constitutes a unique approach to targeted therapy. Inhibition of the proteasome prevents the degradation of numerous regulatory proteins, affecting multiple signaling cascades within the cell, inducing apoptosis.